Drug Approval | February 20, 2023
Briefs: Neuland Laboratories, Cipla and Zydus
Cipla has received 8 inspectional observations in Form 483
Cipla has received 8 inspectional observations in Form 483
There is a fast resurgence in the transplant activities post COVID
The company has also been named among global sustainability leaders for the 7th year in a row in the Dow Jones Sustainability Index in the Emerging Markets category
The Durezol brand and generic had US sales of approximately US $40 million MAT for the most recent twelve months ending in Nov 2022 according to IQVIA
OrbiMed's exercise of warrant conversion will further strengthen the company's net cash position to over Rs.650 crores.
There is a great opportunity for utilizing traditional medical practices like Ayurveda in Value Based Healthcare
Dr. Grant brings to the table significant BOD governance, global business development, and corporate development expertise
In a time when conversations around mental health have become ever more urgent Vaidya’s work is extremely contextual
He urged the dignitaries to collaboratively work on the identified domains of improvement and make detailed reports on them
Dr. Jain is a biotechnology industry veteran with more than two decades of experience in pharmaceutical development across her time with ChemoCentryx, AbbVie, Abbott Laboratories, and G.D. Searle and Co
Subscribe To Our Newsletter & Stay Updated
